Literature DB >> 26256884

[Primary graft failure in a patient with refractory acute myeloid leukemia successfully treated with modified 'one-day'-based preparative regimen followed by cord blood transplantation].

Hiroko Kaiume1, Masahiko Sumi, Takehiko Kirihara, Wataru Takeda, Taro Kurihara, Keijiro Sato, Toshimitsu Ueki, Yuki Hiroshima, Mayumi Ueno, Naoaki Ichikawa, Yuichi Mori, Hikaru Kobayashi.   

Abstract

A 32-year-old woman with acute myeloid leukemia failed to achieve remission with two courses of induction chemotherapy, and she received cord blood transplantation (CBT) in a non-remission state, using an HLA-matched cord blood (CB) graft after a conditioning regimen of fludarabine (Flu) at 125 mg/m² + melphalan at 140 mg/m² + total body irradiation (TBI) at 4 Gy. Chimerism analysis of the bone marrow (BM) cells performed on day 21 after CBT revealed 99% of these cells to be the recipient type. We diagnosed the patient as having graft failure (GF), and then carried out a second CBT using an HLA-matched male CB graft on day 29 after the first CBT. The conditioning regimen (modified 'one-day'-based regimen) consisted of Flu at 30 mg/m² (3 days) + cyclophosphamide (CY) at 2 g/m² (1 day) + TBI 2 Gy. She achieved neutrophil engraftment on day 18. FISH analysis of BM cells on day 13 showed 96% to be of male origin. She has remained in complete remission for 18 months, to date, since the salvage CBT. This case suggests that salvage CBT following a modified 'one-day'-based regimen may preserve a strong graft versus leukemia effect.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26256884     DOI: 10.11406/rinketsu.56.711

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure.

Authors:  Sakurako Suma; Yasuhisa Yokoyama; Haruka Momose; Kenichi Makishima; Yusuke Kiyoki; Tatsuhiro Sakamoto; Manabu Kusakabe; Takayasu Kato; Naoki Kurita; Hidekazu Nishikii; Mamiko Sakata-Yanagimoto; Naoshi Obara; Yuichi Hasegawa; Shigeru Chiba
Journal:  Intern Med       Date:  2021-11-20       Impact factor: 1.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.